I noticed that patients treated with dapagliflozin had a statistically significant increase in their hematocrit. In a recent editorial in JACC: Heart Failure, Vaduganathan et al. discussed that in the Cardio-link 6 Trial empagliflozin increased erythropoietin and suggest that SGLT-2 inhibitors may have other cardiometabolic effects that are beneficial beyond diuretic effect.
What do you think of this hypothesis?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.